Neurogene
New York
About Neurogene
Neurogene is a developer of generic medicines intended to improve patient outcomes for neurological disorders.The company's offerings include advancing genetic medicines for many neurological disorders where no effective treatment options exist, providing patients and families affected by rare neurological disorders with gene therapy that improves quality of life.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Total funding: $383.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2024)
- Ticker: nasdaq:NGNE
- Website: neurogene.com
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/neurogene-8186 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.